IMMX实时信号 | 通过Getagraph.com最大化利润

购买 114797 min ago

@ $3.23

发出时间: 10 Feb 2024 @ 03:14

回报率: -33.95%

上一信号: Feb 8 - 23:29

上一信号: 出售

回报率: 1.20 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia...

Stats
今日成交量	84 843.00
平均成交量	255 953
市值	56.22M
EPS	$-0.255 ( 2024-04-01 )
下一个收益日期	( $-0.230 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.39
ATR14	$0.0170 (0.80%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-11	Hsu Jason	Buy	31 000	Common Stock
2023-12-08	Hsu Jason	Buy	25 000	Common Stock
2023-08-14	Morris Gabriel S	Buy	293 000	Stock Options
2023-08-14	Rachman Ilya M	Buy	293 000	Stock Options
2023-09-15	Hsu Jason	Buy	7 000	Common Stock

INSIDER POWER
99.99
Last 65 transactions
Buy: 7 237 723 \| Sell: 879 400

音量相关性

長: 0.24 (neutral)

短: 0.76 (moderate)

Signal:(42.008) Neutral

Immix Biopharma, Inc. 相关性

10 最正相关
MOMO	0.931
NYMTP	0.93
TOUR	0.928
QFIN	0.924
WB	0.921
OM	0.917
MLCO	0.917
GGAL	0.917
VBNK	0.915
TELA	0.91

10 最负相关
SWAV	-0.921
NVTSW	-0.914
USCB	-0.913
THTX	-0.904
LARK	-0.903
PCRX	-0.899
SNPX	-0.894
PIII	-0.894
GOSS	-0.894
BCAB	-0.892

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Immix Biopharma, Inc. 相关性 - 货币/商品

0.20
( neutral )

-0.33
( neutral )

0.00
( neutral )

0.43
( neutral )

0.06
( neutral )

0.50
( weak )

Immix Biopharma, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-5 468.00 (0.00 %)
EPS:	$-0.890

FY	2023
营收:	$0
毛利润:	$-5 468.00 (0.00 %)
EPS:	$-0.890

FY	2022
营收:	$-89.52M
毛利润:	$-89.52M (100.00 %)
EPS:	$-0.620

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2 907.85

Financial Reports:

No articles found.

Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.